Work

Acute/baseline ratios of all 3 MC mediator metabolites can enhance diagnosis and management of mast cell activation syndrome

Year: 2024

Type: article

Abstract: Background Mast cell (MC) activation syndrome (MCAS) can be a challenge to diagnose and treat despite the near continuous appearance of publications outlining specific criteria. Follow-up of the clinical responses to treatment is often lacking, and confirmation that leukotriene C 4 (LTC 4 ) is an active participant in MCAS has been overlooked. Objective Three patients with MCAS characterized by anaphylaxis are presented to illustrate (1) the value of contemporaneous urinary mediator sampling during MCAS in addition to serum tryptase measurements and (2) substantiation of the fact that not only can LTC 4 (measured metabolite LTE 4 ) be the highest metabolite measured, but (3) blockade of the LTE 4 receptor can contribute to symptom prevention. Method The study methods comprised clinical review and quantitation of acute and baseline levels of tryptase and urinary MC mediators. Results The cases of 3 patients with MCAS are reviewed. In the first case, vespid sting–induced anaphylaxis was associated with a marked increase in the LTE 4 excretion. The addition of montelukast was instituted, and subsequent stings did not evoke symptoms. In the second case, acute measurements showed substantial increased levels of (2,3-dinor)-11β-prostaglandin F 2α , and LTE 4 . The addition of aspirin plus montelukast prevented subsequent attacks. The third case documents a perioperative anaphylactic event with an acute/baseline LTE 4 ratio far higher than those of tryptase or other metabolites. Conclusions The value of measuring all 3 MC mediator metabolites during MCAS should not be overlooked. These measurements can facilitate the successful prevention of attacks. Furthermore, results from these tests show that histamine is often a minor player, whereas acute/baseline levels of the metabolites of LTC 4 and prostaglandin D 2 are frequently much higher, warranting nonantihistamine treatment.

Source: Journal of Allergy and Clinical Immunology Global

DOI: 10.1016/j.jacig.2024.100399

Authors: Joseph H. Butterfield, Adela Taylor

Institutions: Mayo Clinic, Mayo Clinic Health System

Language: English

Topic: Mast cells and histamine

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,000